AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.…
AIM ImmunoTech Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
AIM ImmunoTech (NYSEAMERICAN: AIM) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 19 employees.
The shares were at 0.1146 USD on 20 November 2026, down 95.4% over 52 weeks. Its 52-week range is 0.1068 USD to 2.793 USD: the price is 95.9% below the high and 7.3% above the low.
Its market capitalisation is 4.57M USD.
AIM ImmunoTech reports return on equity of 142.7% and revenue up 4.0% year over year.
It holds more cash than debt, a net cash position of 6.04M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.